<DOC>
	<DOCNO>NCT01115868</DOCNO>
	<brief_summary>There considerable variation scarring , within people , different ethnic group . Individuals pigment skin prone severe scar traditionally term white . Prevascar develop Renovo use potential treatment reduce scar . Renovo 's histological analysis wound scar human non drug study demonstrate increase wound scar width subject African Caribbean ancestry 12 month period . It hypothesise IL-10 may potentially beneficial therapy reduction scar Non Caucasians African-Caribbean ancestry . This Renovo clinical trial carry primarily establish effect four dos Prevascar 1cm incisional excisional scar subject African Continental Group ancestry , compare placebo , investigate safety tolerance intradermally injected Prevascar wound .</brief_summary>
	<brief_title>Prevascar African Continental Group Scarring</brief_title>
	<detailed_description />
	<mesh_term>Cicatrix</mesh_term>
	<criteria>AfroCaribbean male female subject 18 85 year age . Subjects direct question examination history evidence keloid scar . Subjects evidence past present clinically significant medical condition would impair wound heal trial assessment Subjects history clinically significant hypersensitivity drug surgical dressing use trial . Subjects take , take , investigational drug within 3 month prior screen visit . Female subject , become pregnant include Day 0 and/ lactating . In opinion Investigator , subject likely complete trial whatever reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>